Free Trial

ResMed (RMD) Stock Forecast & Price Target

$188.80
+1.86 (+0.99%)
(As of 12:18 PM ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$202.80
7.42% Upside
High Forecast$238.00
Average Forecast$202.80
Low Forecast$165.00
TypeCurrent Forecast
7/3/23 to 7/2/24
1 Month Ago
6/3/23 to 6/2/24
3 Months Ago
4/4/23 to 4/3/24
1 Year Ago
7/3/22 to 7/3/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
5 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$202.80$202.80$199.20$263.43
Forecasted Upside7.42% Upside12.03% Upside12.14% Upside17.72% Upside

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.55
2.70
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.49% Upside832.60% Upside12.47% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Chevrier
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
6/24/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$236.00 ➝ $236.00+14.66%
4/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00-6.23%
4/26/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$227.00 ➝ $238.00+29.75%
3/27/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$215.00+9.88%
URGENT: I’m typing this as fast as I can. (Ad)

I was just informed about something very unsettling… The U.S. Federal Reserve’s computers were allegedly hacked recently. The perpetrators claim to have stolen 33 Terabytes of data, including critical banking information of Americans … Which means all of your banking details could already be in their hands.

Click here and follow the three simple steps Martin shares to protect your savings
1/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$175.00 ➝ $180.00-3.41%
1/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$160.00 ➝ $195.00+7.32%
10/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$180.00 ➝ $169.00+21.82%
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%
9/29/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
9/18/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $230.00+56.36%
1/31/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:50 PM ET.

RMD Forecast - Frequently Asked Questions

What is ResMed's stock forecast and purchase recommendation?

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $202.80, with a high forecast of $238.00 and a low forecast of $165.00. The consensus rating for ResMed stock is Moderate Buy based on the current 5 hold ratings and 6 buy ratings for RMD. Learn more on RMD's analyst rating history.

Do Wall Street analysts like ResMed more than its competitors?

Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.55 while the average consensus rating score for "medical" companies is 2.70. Learn more on how RMD compares to other companies.

Is ResMed being downgraded by Wall Street analysts?

Over the previous 90 days, ResMed's stock had 2 downgrades by analysts.

Does ResMed's stock price have much upside?

According to analysts, ResMed's stock has a predicted upside of 11.69% based on their 12-month stock forecasts.

What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup, KeyCorp, Needham & Company LLC, Oppenheimer, and Royal Bank of Canada in the past 90 days.


This page (NYSE:RMD) was last updated on 7/2/2024 by MarketBeat.com Staff

From Our Partners